A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.
The US$40 million synthetic royalty-backed financing provided by R-Bridge is long-term with flexible and customized repayment schedule to meet Mirxes' near-term strategic priorities. Proceeds from the ...
Blood tests have revealed research results that can increase the accuracy of breast cancer diagnosis.A joint research team of professors Kim Seung-il and Kim ...
Mirxes, a leading Singapore-based cancer detection firm, has secured $40 million in financing from CBC Group's R-Bridge Fund to enhance its innovative miRNA technology platform. The investment aims to ...